Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area.
Rotterdam, Netherlands. In Br J Cancer, Jul 2015
Expression of a comprehensive panel of cancer-testis (MAGE-A1, MAGE-A3/4, MAGE-A10, MAGE-C1, MAGE-C2, NY-ESO-1, SSX-2, sperm protein 17), onco-fetal (AFP, Glypican-3) and overexpressed tumour antigens (Annexin-A2, Wilms tumor-1, Survivin, Midkine, MUC-1) was determined by immunohistochemistry. RESULTS: A higher prevalence of MAGE antigens was observed in patients with hepatitis-B.
The effect of high-intensity circuit training on physical fitness.
Oshkosh, United States. In J Sports Med Phys Fitness, Jun 2015
Following baseline testing for height and weight, body composition, aerobic fitness, muscle strength and muscle endurance, subjects were randomly assigned to one of three groups: 7-minute circuit training (CT-7), 14-minute circuit training (CT-14), and a non-training control group (C).
Cancer-testis antigen expression in digestive tract carcinomas: frequent expression in esophageal squamous cell carcinoma and its precursor lesions.
New York City, United States. In Cancer Immunol Res, 2014
The protein expression of eight cancer-testis antigens [MAGEA, NY-ESO-1, GAGE, MAGEC1 (CT7), MAGEC2 (CT10), CT45, SAGE1, and NXF2] was evaluated by immunohistochemistry in 61 esophageal carcinomas (40 adenocarcinoma and 21 squamous cell carcinoma), 50 gastric carcinomas (34 diffuse and 16 intestinal type), and 141 colorectal carcinomas.
Expression of cancer-testis antigen in multiple myeloma.
Wuhan, China. In J Huazhong Univ Sci Technolog Med Sci, 2014
Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to detect the mRNA expression of MAGE-C1/CT7, SSX1, SSX2 and SSX4 in MM cell lines of RPMI-8226 and U266, and bone marrow (BM) cells of 25 MM patients and 18 healthy volunteers.
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.
Beersheba, Israel. In Ann Rheum Dis, 2001
RESULTS: Patients with malignant diseases may develop autoimmune phenomena and rheumatic diseases as a result of (a) generation of autoantibodies against various autoantigens, including oncoproteins (P185, 1-myc, c-myc, c-myb), tumour suppression genes (P53), proliferation associated antigens (cyclin A, B1, D1, E; CENP-F; CDK, U3-RNP), onconeural antigens (Hu, Yo, Ri, Tr), cancer/testis antigens (MAGE, GAGE, BAGE, SSX, ESO, SCP, CT7), and rheumatic disease associated antigens (RNP, Sm).